BioXcel Therapeutics Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, BioXcel Therapeutics stock has a consensus rating of "Buy" and an average price target of $14. The average 1-year stock price forecast is 1,208.41% higher than the current stock price, while the lowest is $1.00 (-6.54%) and the highest is $38 (+3,451.40%).

Price Target: $14 (+1,208.41%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$1.00	$14	$8.50	$38
Change	-6.54%	+1208.4%	+694.39%	+3451.4%

* Price targets were last updated on Apr 10, 2026.

Analyst Ratings

The average analyst rating for BioXcel Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	3	3	3	3	3	3
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	1	1	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	4	4	4	4	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Ram Selvaraju H.C. Wainwright	H.C. Wainwright	Buy Reiterates $5	Buy	Reiterates	$5	+367.29%	Apr 10, 2026
Alec Stranahan Bank of America Securities	Bank of America Securities	Sell Reiterates $1	Sell	Reiterates	$1	-6.54%	Mar 27, 2026
Michael King Rodman & Renshaw	Rodman & Renshaw	Buy Initiates $17	Buy	Initiates	$17	+1,488.79%	Mar 17, 2026

Financial Forecast

Revenue This Year

769.92K

from 642.00K

19.93%

from 642.00K

Revenue Next Year

18.93M

from 769.92K

2,359.15%

from 769.92K

EPS This Year

-2.62

from -5.71

EPS Next Year

-1.54

from -2.62

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	375.00K	1.38M	2.27M	642.00K	769.92K
Revenue Growth	-	-	268.00%	64.20%	-71.67%	19.93%
Gross Profit	-	355.00K	120.00K	123.00K	478.00K	692.93K
Gross Margin	-	94.67%	8.70%	5.43%	74.45%	90.00%
Operating Income	-106.94M	-159.65M	-167.62M	-64.80M	-50.27M	-42.87M
Net Income	-106.93M	-165.76M	-179.05M	-59.60M	-69.90M	-62.30M
EPS	-	-	-	-	-5.71	-2.62
Free Cash Flow	-42.62M	-75.59M	-96.21M	-48.68M	-39.35M	-54.60M
No. Analysts	-	-	-	-	-	1

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	769,920
Avg	769,920
Low	769,920

Revenue Growth

Revenue Growth	2026	2027	2028
High	19.9%
Avg	19.9%
Low	19.9%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-2.62
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-